The team behind TOXsIgN has invested considerable time, resources, and effort into collecting, curating, processing, developing, and maintaining this web resource.
×
TSP48994-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to rifaximin TSA209921-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin TSA209960-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin TSA210011-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin TSA210065-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin TSA210121-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin TSA210175-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin TSA210227-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin TSA210282-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin TSA210329-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin TSA210365-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin TSA210417-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin TSA210456-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin TSA210509-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin TSF480313-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF480314-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF480315-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF480316-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF480317-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF480318-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF585505-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF585506-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF585507-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF585508-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF585509-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF585510-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF480603-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF480604-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF480605-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF480606-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF480607-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF480608-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF585844-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF585841-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF585846-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF585842-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF585843-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF585845-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF480923-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF480924-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF480922-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF480925-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF480926-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF480927-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF586179-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF586182-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF586177-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF586178-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF586180-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF586181-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF481251-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF481252-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF481253-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF481254-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF481255-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF481256-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF586514-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF586513-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF586515-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF586516-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF586517-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF586518-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF481590-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF481587-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF481588-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF481591-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF481589-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF481592-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF586851-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF586849-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF586850-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF586852-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF586853-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF586854-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF481912-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF481913-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF481914-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF481915-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF481916-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF481917-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF587187-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF587185-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF587186-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF587188-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF587189-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF587190-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF482244-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF482245-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF482246-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF482247-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF482248-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF482249-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF587521-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF587522-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF587523-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF587524-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF587525-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF587526-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF482575-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF482576-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF482577-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF482578-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF482579-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF482580-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF587861-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF587857-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF587858-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF587862-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF587859-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF587860-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF482894-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF482895-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF482893-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF482896-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF482897-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF482898-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF588191-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF588192-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF588193-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF588194-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF588195-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF588196-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF483207-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF483206-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF483208-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF483209-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF483210-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF483211-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF588523-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF588525-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF588524-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF588526-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF588527-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF588528-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF483527-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF483528-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF483529-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF483530-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF483531-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF483532-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF588862-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF588859-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF588857-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF588858-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF588860-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF588861-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF483828-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF483829-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF483827-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF483830-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF483831-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF483832-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF589186-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF589187-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF589190-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF589188-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF589189-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF589191-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSF484159-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 10.0 µM for 24.0 h 1 subfactor(s) TSF484160-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 3.33 µM for 24.0 h 1 subfactor(s) TSF484161-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 1.11 µM for 24.0 h 1 subfactor(s) TSF484162-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.37 µM for 24.0 h 1 subfactor(s) TSF484163-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.125 µM for 24.0 h 1 subfactor(s) TSF484164-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.04 µM for 24.0 h 1 subfactor(s) TSF589521-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 2.22 µM for 24.0 h 1 subfactor(s) TSF589522-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.74 µM for 24.0 h 1 subfactor(s) TSF589523-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.25 µM for 24.0 h 1 subfactor(s) TSF589524-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.08 µM for 24.0 h 1 subfactor(s) TSF589525-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.03 µM for 24.0 h 1 subfactor(s) TSF589526-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.01 µM for 24.0 h 1 subfactor(s) TSS480322-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 10.0 µM for 24.0 h TSS480323-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 3.33 µM for 24.0 h TSS480324-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 1.11 µM for 24.0 h TSS480325-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.37 µM for 24.0 h TSS480326-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.125 µM for 24.0 h TSS480327-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.04 µM for 24.0 h TSS585516-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 2.22 µM for 24.0 h TSS585517-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.74 µM for 24.0 h TSS585518-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.25 µM for 24.0 h TSS585519-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.08 µM for 24.0 h TSS585520-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.03 µM for 24.0 h TSS585521-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A375 after exposure to rifaximin 0.01 µM for 24.0 h TSS480612-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 10.0 µM for 24.0 h TSS480613-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 3.33 µM for 24.0 h TSS480614-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 1.11 µM for 24.0 h TSS480615-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.37 µM for 24.0 h TSS480616-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.125 µM for 24.0 h TSS480617-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.04 µM for 24.0 h TSS585855-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.08 µM for 24.0 h TSS585852-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 2.22 µM for 24.0 h TSS585857-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.01 µM for 24.0 h TSS585853-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.74 µM for 24.0 h TSS585854-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.25 µM for 24.0 h TSS585856-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line A549 after exposure to rifaximin 0.03 µM for 24.0 h TSS480932-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 3.33 µM for 24.0 h TSS480933-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 1.11 µM for 24.0 h TSS480931-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 10.0 µM for 24.0 h TSS480934-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.37 µM for 24.0 h TSS480935-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.125 µM for 24.0 h TSS480936-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.04 µM for 24.0 h TSS586190-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.25 µM for 24.0 h TSS586193-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.01 µM for 24.0 h TSS586188-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 2.22 µM for 24.0 h TSS586189-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.74 µM for 24.0 h TSS586191-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.08 µM for 24.0 h TSS586192-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HA1E after exposure to rifaximin 0.03 µM for 24.0 h TSS481260-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 10.0 µM for 24.0 h TSS481261-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 3.33 µM for 24.0 h TSS481262-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 1.11 µM for 24.0 h TSS481263-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.37 µM for 24.0 h TSS481264-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.125 µM for 24.0 h TSS481265-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.04 µM for 24.0 h TSS586525-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.74 µM for 24.0 h TSS586524-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 2.22 µM for 24.0 h TSS586526-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.25 µM for 24.0 h TSS586527-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.08 µM for 24.0 h TSS586528-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.03 µM for 24.0 h TSS586529-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HEK293 after exposure to rifaximin 0.01 µM for 24.0 h TSS481599-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.37 µM for 24.0 h TSS481596-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 10.0 µM for 24.0 h TSS481597-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 3.33 µM for 24.0 h TSS481600-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.125 µM for 24.0 h TSS481598-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 1.11 µM for 24.0 h TSS481601-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.04 µM for 24.0 h TSS586862-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.25 µM for 24.0 h TSS586860-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 2.22 µM for 24.0 h TSS586861-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.74 µM for 24.0 h TSS586863-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.08 µM for 24.0 h TSS586864-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.03 µM for 24.0 h TSS586865-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HELA after exposure to rifaximin 0.01 µM for 24.0 h TSS481921-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 10.0 µM for 24.0 h TSS481922-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 3.33 µM for 24.0 h TSS481923-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 1.11 µM for 24.0 h TSS481924-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.37 µM for 24.0 h TSS481925-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.125 µM for 24.0 h TSS481926-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.04 µM for 24.0 h TSS587198-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.25 µM for 24.0 h TSS587196-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 2.22 µM for 24.0 h TSS587197-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.74 µM for 24.0 h TSS587199-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.08 µM for 24.0 h TSS587200-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.03 µM for 24.0 h TSS587201-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line HT29 after exposure to rifaximin 0.01 µM for 24.0 h TSS482253-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 10.0 µM for 24.0 h TSS482254-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 3.33 µM for 24.0 h TSS482255-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 1.11 µM for 24.0 h TSS482256-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.37 µM for 24.0 h TSS482257-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.125 µM for 24.0 h TSS482258-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.04 µM for 24.0 h TSS587532-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 2.22 µM for 24.0 h TSS587533-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.74 µM for 24.0 h TSS587534-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.25 µM for 24.0 h TSS587535-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.08 µM for 24.0 h TSS587536-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.03 µM for 24.0 h TSS587537-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line JURKAT after exposure to rifaximin 0.01 µM for 24.0 h TSS482584-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 10.0 µM for 24.0 h TSS482585-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 3.33 µM for 24.0 h TSS482586-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 1.11 µM for 24.0 h TSS482587-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.37 µM for 24.0 h TSS482588-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.125 µM for 24.0 h TSS482589-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.04 µM for 24.0 h TSS587872-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.03 µM for 24.0 h TSS587868-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 2.22 µM for 24.0 h TSS587869-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.74 µM for 24.0 h TSS587873-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.01 µM for 24.0 h TSS587870-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.25 µM for 24.0 h TSS587871-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF10A after exposure to rifaximin 0.08 µM for 24.0 h TSS482903-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 3.33 µM for 24.0 h TSS482904-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 1.11 µM for 24.0 h TSS482902-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 10.0 µM for 24.0 h TSS482905-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.37 µM for 24.0 h TSS482906-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.125 µM for 24.0 h TSS482907-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.04 µM for 24.0 h TSS588202-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 2.22 µM for 24.0 h TSS588203-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.74 µM for 24.0 h TSS588204-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.25 µM for 24.0 h TSS588205-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.08 µM for 24.0 h TSS588206-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.03 µM for 24.0 h TSS588207-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MCF7 after exposure to rifaximin 0.01 µM for 24.0 h TSS483216-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 3.33 µM for 24.0 h TSS483215-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 10.0 µM for 24.0 h TSS483217-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 1.11 µM for 24.0 h TSS483218-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.37 µM for 24.0 h TSS483219-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.125 µM for 24.0 h TSS483220-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.04 µM for 24.0 h TSS588534-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 2.22 µM for 24.0 h TSS588536-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.25 µM for 24.0 h TSS588535-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.74 µM for 24.0 h TSS588537-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.08 µM for 24.0 h TSS588538-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.03 µM for 24.0 h TSS588539-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line MDAMB231 after exposure to rifaximin 0.01 µM for 24.0 h TSS483536-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 10.0 µM for 24.0 h TSS483537-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 3.33 µM for 24.0 h TSS483538-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 1.11 µM for 24.0 h TSS483539-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.37 µM for 24.0 h TSS483540-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.125 µM for 24.0 h TSS483541-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.04 µM for 24.0 h TSS588873-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.01 µM for 24.0 h TSS588870-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.25 µM for 24.0 h TSS588868-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 2.22 µM for 24.0 h TSS588869-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.74 µM for 24.0 h TSS588871-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.08 µM for 24.0 h TSS588872-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line PC3 after exposure to rifaximin 0.03 µM for 24.0 h TSS483837-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 3.33 µM for 24.0 h TSS483838-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 1.11 µM for 24.0 h TSS483836-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 10.0 µM for 24.0 h TSS483839-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.37 µM for 24.0 h TSS483840-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.125 µM for 24.0 h TSS483841-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.04 µM for 24.0 h TSS589197-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 2.22 µM for 24.0 h TSS589198-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.74 µM for 24.0 h TSS589201-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.03 µM for 24.0 h TSS589199-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.25 µM for 24.0 h TSS589200-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.08 µM for 24.0 h TSS589202-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line THP1 after exposure to rifaximin 0.01 µM for 24.0 h TSS484168-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 10.0 µM for 24.0 h TSS484169-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 3.33 µM for 24.0 h TSS484170-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 1.11 µM for 24.0 h TSS484171-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.37 µM for 24.0 h TSS484172-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.125 µM for 24.0 h TSS484173-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.04 µM for 24.0 h TSS589532-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 2.22 µM for 24.0 h TSS589533-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.74 µM for 24.0 h TSS589534-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.25 µM for 24.0 h TSS589535-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.08 µM for 24.0 h TSS589536-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.03 µM for 24.0 h TSS589537-CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures in the human cell line YAPC after exposure to rifaximin 0.01 µM for 24.0 h
TSP48994 - CMap - Expanded CMap LINCS Resource 2020: Toxicogenomic signatures after exposure to rifaximin
Public
https://clue.io/data/CMap2020#LINCS2020
Experimental design
No experimental design provided
Results
No results provided